• Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial | The BMJ
    https://www.bmj.com/content/363/bmj.k5094

    Abstract

    Objective To determine if using a parachute prevents death or major traumatic injury when jumping from an aircraft.

    Design Randomized controlled trial.

    Setting Private or commercial aircraft between September 2017 and August 2018.

    Participants 92 aircraft passengers aged 18 and over were screened for participation. 23 agreed to be enrolled and were randomized.

    Intervention Jumping from an aircraft (airplane or helicopter) with a parachute versus an empty backpack (unblinded).

    Main outcome measures Composite of death or major traumatic injury (defined by an Injury Severity Score over 15) upon impact with the ground measured immediately after landing.

    Results Parachute use did not significantly reduce death or major injury (0% for parachute v 0% for control; P>0.9). This finding was consistent across multiple subgroups. Compared with individuals screened but not enrolled, participants included in the study were on aircraft at significantly lower altitude (mean of 0.6 m for participants v mean of 9146 m for non-participants; P<0.001) and lower velocity (mean of 0 km/h v mean of 800 km/h; P<0.001).

    Conclusions Parachute use did not reduce death or major traumatic injury when jumping from aircraft in the first randomized evaluation of this intervention. However, the trial was only able to enroll participants on small stationary aircraft on the ground, suggesting cautious extrapolation to high altitude jumps. When beliefs regarding the effectiveness of an intervention exist in the community, randomized trials might selectively enroll individuals with a lower perceived likelihood of benefit, thus diminishing the applicability of the results to clinical practice.

    Ça rappelle les trottinettes anti-covid ça...

    • Même logique à propos des 30 000 qui prouvent des trucs :
      https://twitter.com/MahmoudZureik/status/1663531173493055488

      C’est un autre biais qui est rarement décrit (car impensable à se produire dans étude sérieuse) que j’appelle le « biais de contre-indication ».

      L’HCQ a été donné systématiquement à tous les patients sauf à ceux pour lesquels l’HCQ est contre indiqué (problèmes cardiaques,…)

      C’est pour cette raison et comme l’a dit D Raoult lui-même sur BFM, on fait des tests biologiques et un électrocardiogramme avant de le prescrire.

      L’état de santé des personnes qui n’ont pas pris ce médicament est plus sérieux et plus grave que celles qui ne l’ont pas pris.

      Donc l’étude compare les patients ayant pu prendre l’HCQ car jeunes et en bonne santé à des patients âgés et fragiles qui ne peuvent pas le recevoir et qui sont à risque plus élevé de mortalité.